購物車 
-
Gitoformate
- names：
Gitoformate
- CAS號：
10176-39-3
MDL Number： - MF(分子式)： C46H64O19 MW(分子量)： 921
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數(shù)量 | 總計 (￥) |
|---|
| 中文別名 | (2R,3R,4S,6S)-6-(((2R,3R,4S,6S)-4-(formyloxy)-6-(((2R,3R,4S,6R)-4-(formyloxy)-6-(((3S,5R,8R,9S,10S,13R,14S,16S,17R)-16-(formyloxy)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3,4-diyl diformate |
| 英文別名 | Gitoformate; Formiloxin; Pentaformylgitoxin; AC 2770 |
| CAS號 | 10176-39-3 |
| Inchi | InChI=1S/C46H64O19/c1-24-41(59-23-51)32(55-19-47)14-38(60-24)64-43-26(3)62-39(16-34(43)57-21-49)65-42-25(2)61-37(15-33(42)56-20-48)63-29-8-10-44(4)28(13-29)6-7-31-30(44)9-11-45(5)40(27-12-36(52)54-18-27)35(58-22-50)17-46(31,45)53/h12,19-26,28-35,37-43,53H,6-11,13-18H2,1-5H3/t24-,25-,26-,28-,29+,30+,31-,32+,33+,34+,35+,37+,38+,39+,40+,41-,42-,43-,44+,45-,46+/m1/s1 |
| InchiKey | DOMHWKQEPDYUQX-LJAQBGIBSA-N |
| 分子式 Formula | C46H64O19 |
| 分子量 Molecular Weight | 921 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說明 | Gitoformate(CAS:10176-39-3):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Gitoformate is used to treat cardiac and renal insufficiency, |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Kubin S, Woodcock BG, Menke G, Rietbrock N. [Postprandial delay of drug absorption in a gitoformate model]. Arzneimittelforschung. 1987 Dec;37(12):1376-8. German. PubMed PMID: 3449065. |
| [2]Reuter N, Meyer F. [Effects of pentaformylgitoxin (gitoformate) on the cardiovascular system of anesthetized cats]. Arzneimittelforschung. 1976;26(6):1201-5. German. PubMed PMID: 989416. |
| [3] Dei Cas L, Manca C, Assanelli D, Vasini G, Pelagatti T, Buia E. [Pharmacokinetics and pharmacodynamics of gitoformate in subjects with atrial fibrillation]. Boll Soc Ital Cardiol. 1981;26(12):2383-4. Italian. PubMed PMID: 7185409. |
| [4] Dei Cas L, Vasini G, Manca C, Buia E, Pelagatti T, Bernardini B. [Pharmacokinetics of gitoformate in subjects with renal insufficiency under dialysis treatment]. Boll Soc Ital Cardiol. 1981;26(12):2381-2. Italian. PubMed PMID: 7185408. |
| [5] Lesne M, Cremers S, Carlier J. [Pharmacokinetic and biopharmaceutic parameters of gitoformate]. Therapie. 1978 Nov-Dec;33(6):723-34. French. PubMed PMID: 746519. |
6: Rietbrock N, Woodcock BG, Hrazdil U. [Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]. Arzneimittelforschung. 1984;34(8):915-7. German. PubMed PMID: 6541927.7: Dei Cas L, Vasini G, Bianchi G, Manca C, Ghinelli R, Mansour M. [Gitoformate in chronic renal insufficiency: pharmacokinetic aspects]. Boll Soc Ital Cardiol. 1979;24(2):209-12. Italian. PubMed PMID: 548097.8: Dei Cas L, Biasucci LM, Buia E, Frustaci A, Manca C, Metra M, Rebuzzi AG. [Circadian aspects of the heart rate in atrial fibrillation patients: the comparative effect of digoxin and pentaformylgitoxin]. Cardiologia. 1983 Dec;28(12):1019-25. Italian. PubMed PMID: 6681261.9: Kesteloot H, Brasseur L, Carlier J, Demanet JC, Andriange M, Bataille G, Collignon P, Cosyns J, Vancrombreucq JC, Van Durme JP, Willems J, Foucart G. Effect of digitalis on the left ventricular ejection time: a multicenter double-blind comparative study of digitoxin and pentaformylgitoxin in normal subjects. Acta Cardiol. 1969;24(4):409-25. PubMed PMID: 4928444.10: Dei Cas L, Biasucci LM, Buia E, Frustaci A, Manca C, Metra M, Rebuzzi AG. [Circadian aspects of heart rate in patients with atrial fibrillation: comparative influence of digoxin and pentaformylgitoxin]. Cardiologia. 1983 Dec;28(12):1019-25. Italian. PubMed PMID: 6687204.1
對不起，暫無產(chǎn)品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養(yǎng)基內(nèi)，細胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術(shù)與國際市場的雙重突破
在實驗室耗材領(lǐng)域，封口膜是保障實驗準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
熒光素鉀鹽使用說明
D-熒光素鉀鹽（K+）設(shè)計用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實驗室中是通用的，可用于蛋白質(zhì)印跡、細胞組織培養(yǎng)、P...
2022/10/19 9:39:51
